Kymera Therapeutics, Inc.
KYMRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Kymera Therapeutics, Inc. focuses on Biotechnology services and products. Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by. With a market capitalization of $9.58B, it sits in mid-cap territory. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Market Cap
$9.58B
Beta
1.97
P/E (TTM)
—
P/E (Fwd)
-23.52
EPS (TTM)
$-3.25
EPS (Fwd)
$-4.95
ROE
-24.1%
ROA
-15.6%
Cash
$691.0M
Total Debt
$78.6M
Free CF
-$144.1M
52W Change
170.0%
Annual Financials
Cash vs Debt
Where KYMR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KYMR finished 27.20% above its 150-day moving average ($93.26) and 33.95% above its 200-day moving average ($88.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KYMR overbought or oversold?
At the September 3, 2026 close, KYMR's RSI(14) was 55.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $691.0M in cash comfortably exceeding the $78.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$144.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -24.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $46.8M (2022) to $39.2M (2025), a 16% decline worth watching.
Kymera Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, KYMR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kymera Therapeutics, Inc.'s trajectory.